

Special Issue

Biomarkers for Skin Cancer Patients

Message from the Guest Editor

Cancer biomarkers can be measured in blood, organ tissue, or bodily fluids, and are increasingly used to identify the presence of malignancy and help to determine its stage, subtype, and whether a patient will respond to treatment, experience recurrent disease, or even die from cancer. Today, biomarkers play a crucial role in the diagnosis, therapy, and management of patients suffering from skin malignancies. On the other hand, biomarkers are increasingly established to detect patients with more favorable prognosis who may safely waive over-treatment. Moreover, biomarkers may help to identify patients who are at lower risk and may therefore undergo a follow-up regimen that is less strict. However, there are still challenges in the development of novel noninvasive biomarkers with greater clinical performance. The present Special Issue particularly focusses on original research findings and reviews on skin cancer biomarkers, which may include (but are not limited to) genetic, genomic, epigenomic, proteomic, cellular, and morphologic factors predisposing to skin cancers, indicating the presence of skin cancer, or correlating with treatment response and disease outcome.

Guest Editor

Prof. Dr. Thilo Gambichler

1. Department of Dermatology, Christian Hospital Unna, Unna, Germany
2. Department of Dermatology, Dortmund Hospital gGmbH, University Witten/Herdecke, Witten, Germany

Deadline for manuscript submissions

closed (30 September 2022)



Dermato

an Open Access Journal
by MDPI

Indexed in Scopus



mdpi.com/si/116433

Dermato
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
dermato@mdpi.com

[mdpi.com/journal/
dermato](https://mdpi.com/journal/dermato)





Dermato

an Open Access Journal
by MDPI

Indexed in Scopus



[mdpi.com/journal/
dermato](https://mdpi.com/journal/dermato)



About the Journal

Message from the Editorial Board

Editors-in-Chief

Prof. Dr. Chalid Assaf

1. Department of Dermatology and Venerology, Helios Klinikum Krefeld, Krefeld, Germany
2. Institute of Molecular Medicine, Medical School Hamburg, Hamburg, Germany

Prof. Dr. Thilo Gambichler

1. Department of Dermatology, Christian Hospital Unna, Unna, Germany
2. Department of Dermatology, Dortmund Hospital gGmbH, University Witten/Herdecke, Witten, Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25.1 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the first half of 2025).